zinc finger protein 402, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ZNF402P profile across patient tissues and cancer cell-line models. ZNF402P expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF402P is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, ZNF402P RNA expression shows 6,519 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, LUAD, and STAD as cancer lineages where ZNF402P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF402P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF402P survival associations across molecular data types. ZNF402P RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF402P RNA expression–survival associations across cancer types. High ZNF402P expression shows unfavorable associations in MESO, CHOL, LUSC, UVM, LGG and READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF402P RNA expression.
This table summarizes ZNF402P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF402P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF402P shows lower tumor expression in THCA and higher tumor expression in LUAD, BLCA, HNSC, LUSC and PAAD. The LUAD box plot shows higher ZNF402P RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p = .001).
This table shows molecular features associated with ZNF402P in patient tissues and cancer cell lines. In patient samples, ZNF402P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
